ANNX | Annexon, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	5.54 - 6.00
52 Week Range	1.5700 - 8.40
Beta	1.18
Implied Volatility	66.68%
IV Rank	24.39%
Day's Volume	575,891
Average Volume	1,554,591
Shares Outstanding	105,654,000
Market Cap	607,510,500
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-07-24

Valuation
Profitability
Growth
Health
P/E Ratio	-4.75
Forward P/E Ratio	N/A
EPS	-1.21
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	70
Country	USA
Website	ANNX

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

ANNX's peers: ALLK, ALLO, IMMX, CNSP, HEPA, FRLN, AVRO, DAWN, ABOS, XFOR, INZY, VECT, ISEE, BPMC, AMLX, KRTX, RCUS, CGEM, GPCR, RLAY, ZURA, ICVX, INAB, WVE, ARWR, CGEN, CNTX, GHRS, GRTS, GTHX, IPA, ITOS, LGND, NBTX, NERV, PRQR, SLNO, TCRX, VNDA, VYGR, ZNTL, ZYME, ERNA, SPRY

*Chart delayed

Analyzing fundamentals for ANNX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see ANNX Fundamentals page.

Watching at ANNX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ANNX Technicals page.